212 related articles for article (PubMed ID: 21602513)
1. The soluble CTLA-4 splice variant protects from type 1 diabetes and potentiates regulatory T-cell function.
Gerold KD; Zheng P; Rainbow DB; Zernecke A; Wicker LS; Kissler S
Diabetes; 2011 Jul; 60(7):1955-63. PubMed ID: 21602513
[TBL] [Abstract][Full Text] [Related]
2. Alternative splice forms of CTLA-4 induced by antisense mediated splice-switching influences autoimmune diabetes susceptibility in NOD mice.
Mourich DV; Oda SK; Schnell FJ; Crumley SL; Hauck LL; Moentenich CA; Marshall NB; Hinrichs DJ; Iversen PL
Nucleic Acid Ther; 2014 Apr; 24(2):114-26. PubMed ID: 24494586
[TBL] [Abstract][Full Text] [Related]
3. Genetic evidence that the differential expression of the ligand-independent isoform of CTLA-4 is the molecular basis of the Idd5.1 type 1 diabetes region in nonobese diabetic mice.
Araki M; Chung D; Liu S; Rainbow DB; Chamberlain G; Garner V; Hunter KM; Vijayakrishnan L; Peterson LB; Oukka M; Sharpe AH; Sobel R; Kuchroo VK; Wicker LS
J Immunol; 2009 Oct; 183(8):5146-57. PubMed ID: 19783679
[TBL] [Abstract][Full Text] [Related]
4. CT60 genotype does not affect CTLA-4 isoform expression despite association to T1D and AITD in northern Sweden.
Mayans S; Lackovic K; Nyholm C; Lindgren P; Ruikka K; Eliasson M; Cilio CM; Holmberg D
BMC Med Genet; 2007 Feb; 8():3. PubMed ID: 17280620
[TBL] [Abstract][Full Text] [Related]
5. Increased production of soluble CTLA-4 in patients with spondylarthropathies correlates with disease activity.
Toussirot E; Saas P; Deschamps M; Pouthier F; Perrot L; Perruche S; Chabod J; Tiberghien P; Wendling D
Arthritis Res Ther; 2009; 11(4):R101. PubMed ID: 19570209
[TBL] [Abstract][Full Text] [Related]
6. A SNP in the Immunoregulatory Molecule CTLA-4 Controls mRNA Splicing In Vivo but Does Not Alter Diabetes Susceptibility in the NOD Mouse.
Jakubczik F; Jones K; Nichols J; Mansfield W; Cooke A; Holmes N
Diabetes; 2016 Jan; 65(1):120-8. PubMed ID: 26450994
[TBL] [Abstract][Full Text] [Related]
7. The B7-independent isoform of CTLA-4 functions to regulate autoimmune diabetes.
Stumpf M; Zhou X; Bluestone JA
J Immunol; 2013 Feb; 190(3):961-9. PubMed ID: 23293354
[TBL] [Abstract][Full Text] [Related]
8. Investigation of soluble and transmembrane CTLA-4 isoforms in serum and microvesicles.
Esposito L; Hunter KM; Clark J; Rainbow DB; Stevens H; Denesha J; Duley S; Dawson S; Coleman G; Nutland S; Bell GL; Moran C; Pekalski M; Todd JA; Wicker LS
J Immunol; 2014 Jul; 193(2):889-900. PubMed ID: 24928993
[TBL] [Abstract][Full Text] [Related]
9. Targeting the alternatively spliced soluble isoform of CTLA-4: prospects for immunotherapy?
Ward FJ; Dahal LN; Khanolkar RC; Shankar SP; Barker RN
Immunotherapy; 2014; 6(10):1073-84. PubMed ID: 25428646
[TBL] [Abstract][Full Text] [Related]
10. Ctla-4 controls regulatory T cell peripheral homeostasis and is required for suppression of pancreatic islet autoimmunity.
Schmidt EM; Wang CJ; Ryan GA; Clough LE; Qureshi OS; Goodall M; Abbas AK; Sharpe AH; Sansom DM; Walker LS
J Immunol; 2009 Jan; 182(1):274-82. PubMed ID: 19109158
[TBL] [Abstract][Full Text] [Related]
11. Brief report: increased expression of a short splice variant of CTLA-4 exacerbates lupus in MRL/lpr mice.
Ichinose K; Zhang Z; Koga T; Juang YT; Kis-Tóth K; Sharpe AH; Kuchroo V; Crispín JC; Tsokos GC
Arthritis Rheum; 2013 Mar; 65(3):764-9. PubMed ID: 23203389
[TBL] [Abstract][Full Text] [Related]
12. An autoimmune disease-associated CTLA4 splice variant lacking the B7 binding domain signals negatively in T cells.
Vijayakrishnan L; Slavik JM; Illés Z; Rainbow D; Peterson LB; Sharpe AS; Wicker LS; Kuchroo VK
Novartis Found Symp; 2005; 267():200-12; discussion 212-8. PubMed ID: 15999808
[TBL] [Abstract][Full Text] [Related]
13. Opposing effects of CTLA4 insufficiency on regulatory versus conventional T cells in autoimmunity converge on effector memory in target tissue.
Devarajan P; Miska J; Lui JB; Swieboda D; Chen Z
J Immunol; 2014 Nov; 193(9):4368-80. PubMed ID: 25246499
[TBL] [Abstract][Full Text] [Related]
14. The soluble isoform of CTLA-4 as a regulator of T-cell responses.
Ward FJ; Dahal LN; Wijesekera SK; Abdul-Jawad SK; Kaewarpai T; Xu H; Vickers MA; Barker RN
Eur J Immunol; 2013 May; 43(5):1274-85. PubMed ID: 23400950
[TBL] [Abstract][Full Text] [Related]
15. Soluble CTLA-4 attenuates T cell activation and modulates anti-tumor immunity.
Kennedy PT; Saulters EL; Duckworth AD; Lim YJ; Woolley JF; Slupsky JR; Cragg MS; Ward FJ; Dahal LN
Mol Ther; 2024 Feb; 32(2):457-468. PubMed ID: 38053333
[TBL] [Abstract][Full Text] [Related]
16. Soluble CTLA-4 receptor an immunological marker of Graves' disease and severity of ophthalmopathy is associated with CTLA-4 Jo31 and CT60 gene polymorphisms.
Daroszewski J; Pawlak E; Karabon L; Frydecka I; Jonkisz A; Slowik M; Bolanowski M
Eur J Endocrinol; 2009 Nov; 161(5):787-93. PubMed ID: 19734241
[TBL] [Abstract][Full Text] [Related]
17. Lack of association between sCTLA-4 levels in human plasma and common CTLA-4 polymorphisms.
Berry A; Tector M; Oaks MK
J Negat Results Biomed; 2008 Nov; 7():8. PubMed ID: 19014504
[TBL] [Abstract][Full Text] [Related]
18. In vitro Treg expansion favors the full-length splicing isoform of CTLA4.
Kaartinen T; Harjunpää H; Partanen J; Tiittanen M
Immunotherapy; 2016 May; 8(5):541-53. PubMed ID: 27140408
[TBL] [Abstract][Full Text] [Related]
19. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease.
Ueda H; Howson JM; Esposito L; Heward J; Snook H; Chamberlain G; Rainbow DB; Hunter KM; Smith AN; Di Genova G; Herr MH; Dahlman I; Payne F; Smyth D; Lowe C; Twells RC; Howlett S; Healy B; Nutland S; Rance HE; Everett V; Smink LJ; Lam AC; Cordell HJ; Walker NM; Bordin C; Hulme J; Motzo C; Cucca F; Hess JF; Metzker ML; Rogers J; Gregory S; Allahabadia A; Nithiyananthan R; Tuomilehto-Wolf E; Tuomilehto J; Bingley P; Gillespie KM; Undlien DE; Rønningen KS; Guja C; Ionescu-Tîrgovişte C; Savage DA; Maxwell AP; Carson DJ; Patterson CC; Franklyn JA; Clayton DG; Peterson LB; Wicker LS; Todd JA; Gough SC
Nature; 2003 May; 423(6939):506-11. PubMed ID: 12724780
[TBL] [Abstract][Full Text] [Related]
20. The soluble CTLA-4 receptor: a new marker in autoimmune diseases.
Pawlak E; Kochanowska IE; Frydecka I; Kiełbiński M; Potoczek S; Bilińska M
Arch Immunol Ther Exp (Warsz); 2005; 53(4):336-41. PubMed ID: 16088318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
